Amy K. LeBlanc, D.V.M.

Amy K. LeBlanc, D.V.M.
Staff Scientist
Director, Comparative Oncology Program

As Director of the Comparative Oncology Program, Dr. LeBlanc has a strong interest in animal modeling for development of new cancer drugs and imaging agents, and identification of imaging biomarkers, development and optimization of PET imaging hardware and imaging protocols.

Areas of Expertise
1) animal models, 2) imaging, 3) biomarker identification

Contact Info

Amy K. LeBlanc, D.V.M.
Center for Cancer Research
National Cancer Institute
Building 37, Room 5000
Bethesda, MD 20892
Ph: 301-594-2570
amy.leblanc@nih.gov

Dr. LeBlanc has a strong interest in animal modeling for development of new cancer drugs and imaging agents, and identification of imaging biomarkers, development and optimization of PET imaging hardware and imaging protocols. She has experience in fostering collaborations with industry and academic partners to support relevant eIND studies in man. She has given numerous invited lectures on the inclusion of companion animals in imaging-based translational research and the value of comparative oncology in drug and imaging agent development.

Scientific Focus Areas:
Cancer Biology

Selected Recent Publications

  1. LeBlanc AK.
    ILAR J. 55(1): 164-8, 2014. [ Journal Article ]
  2. LeBlanc AK and Peremans K.
    Semin Nucl Med. 44(1):: 47-56, 2014. [ Journal Article ]
  3. Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred Beagle dogs.
    LeBlanc AK, Naik S, Galyon G, Jenks N, Steele M, Peng KW, Federspiel MJ, Donnell R, and Russell SJ.
    Hum Gene Ther Clin Dev. 24(4): 174-81, 2013. [ Journal Article ]
  4. Stout D, Berr SS, LeBlanc A, Kalen JD, Osborne D, Price J, Schiffer W, Kuntner C, and Wall J.
    Mol Imaging. 12(7): 1-15, 2013. [ Journal Article ]
  5. Paoloni M, Tandle A, Mazcko C, Hanna E, LeBlanc A, Vail D, Henry C, Sorenmo K, Thamm D, Kachala S, Newman S, Pasqualini R, Arap W, Khanna C, and Libutti S.
    PLoS One. 4(3): 1-11, 2009. [ Journal Article ]

Dr. Amy LeBlanc is a board-certified veterinary oncologist and Director of the CCR Comparative Oncology Program at the National Cancer Institute, NIH. In this position, she directly oversees and manages the operations of the Comparative Oncology Trials Consortium (COTC), which designs and executes clinical trials of new cancer therapies in tumor-bearing pet dogs.

Dr. LeBlanc is a graduate of Michigan State University, holding both B.S. and D.V.M. degrees. She completed a rotating internship in small animal medicine and surgery at Texas A&M University and a residency in companion animal oncology at Louisiana State University. She is board-certified by the American College of Veterinary Internal Medicine.

Prior to her appointment at NIH, Dr. LeBlanc was an Associate Professor with tenure and Director of Translational Research at the University of Tennessee College of Veterinary Medicine (CVM) and UT Graduate School of Medicine (GSM). Dr. LeBlanc’s group at the University of Tennessee published the first comprehensive studies describing molecular imaging of dogs and cats using PET/CT, focusing on the forward and back-translation of 18F-labelled radiopharmaceuticals.

Dr. LeBlanc has given numerous invited lectures on the inclusion of companion animals in imaging-based translational research and the value of comparative oncology in drug and imaging agent development.

Name Position
Shan Huang M.D., Ph.D. Postdoctoral Fellow (Visiting)
Ling Ren Ph.D. Biologist
Christina Mazcko Biologist